Allogeneic minitransplants are being increasingly used for the treatment of hematologic malignancies. Eligibility criteria usually include age over 60 years and/or major clinical problems concomitant with the hematologic disorder. This report summarizes a workshop which was held in 1999 under the auspices of EBMT: the issues discussed included stem cell sources and mobilization techniques, stem cell engraftment, accessory cells, mixed chimerism, graft-versus-tumor effect and ongoing clinical trials. There are many questions which still need to be answered, but this area of transplantation seems very promising and will certainly develop in the coming years. Bone Marrow Transplantation (2000) 25, 803-805. Keywords: low intensity conditioning; engraftment; chimerism; GVL Unfractionated allogeneic hematopoietic stem cell transplantation (HSCT) following high-dose chemoradiotherapy is associated with a considerable risk of acute graft-versushost disease (GVHD), leading to significant morbidity and mortality. Age is an important prognostic factor for treatment-related mortality (TRM) which increases by each decade. This is true for HLA-identical sibling transplants, and more so for alternative donor transplants. T cell depletion (TCD) prevents GVHD but is associated with rejection problems and leukemia relapse, such that intensified conditioning regimens are needed with single-dose total body irradiation (TBI) and high-dose myeloablative agents. Age limitations thus remain in both unfractionated and TCD grafts. Recently, low-dose total body irradiation TBI and fludarabine containing regimens -so called 'minitransplants' -have been explored in preparation for allogeneic HSCT.
vened in Zurich on 5 and 6 February 1999. This is a report from that workshop.
Stem cell sources, expansion and mobilization
Bone marrow has been widely used as a source of stem cells (SC) for both animal models and clinical transplantation. Alternative sources include cord blood and peripheral blood. The problem of cord blood is the small total number of progenitors, especially for an adult recipient: expansion of such progenitors preserves their phenotype and increases their number, but at the expense of their radioprotective capacity. Peripheral blood is the other, now very popular, alternative source of stem cells and mobilization techniques were discussed. For patients with malignancies cyclophosphamide (CY) 4-7 g/m 2 followed by granulocyte colony-stimulating factor (G-CSF) mobilizes approximately 2 × 10 6 /kg CD34 + cells in 3 liters of blood. The addition of stem cell factor (SCF) increases the yield of CD34
+ cells by 30-to 100-fold, thus making it possible to use small quantities of whole blood instead of leukapheresis products. In Manchester, a pilot study is ongoing in lymphoma patients mobilized with CY+GCSF+SCF: a small volume of whole blood is then collected and CD34 + cells used for autotransplantation.
Alternative mobilization procedures include the use of chemokines and antibodies. In vivo administration of IL-8 results in mobilization of SC in the peripheral blood within 30 min and is dependent on the presence of neutrophils.
Stem cell engraftment
Hematopoietic stem cells (HSC) are quiescent but can move into cycle after HSCT. Their capacity to engraft depends on their cell cycle status: cells in S phase or G2 have low engraftment capacity and the contrary is true for cells in G0. In the presence of stem cell factor, stem cells move very rapidly and expose projections called microspikes. Engraftment is determined by stem cell competition and treatment of the host: with 1 Gy TBI up to 70% engraftment is achieved, and with higher doses of TBI 100% engraftment is achieved. The use of post-graft immunosuppression is also essential.
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The role of accessory cells
The relevance of T cells for stem cell engraftment is now clear, since TCD leads to a greater risk of graft rejection and graft failure. This facilitating effect may be accomplished by suppression of host immune function, but also via growth factors or direct interaction with stem cells, as we now appreciate the regulatory capacity of T cells on hematopoiesis. Unfortunately, we still do not know which T cell subpopulation is involved, and this has impaired the development of selective T cell depletion or add-back programs. Other cells are being explored for their effect on engraftment.
Mixed hematopoietic chimerism
The coexistence of both host and donor hematopoietic stem cells after allogeneic transplantation is referred to as mixed chimerism and is seen in patients receiving reduced intensity conditioning regimens, Several thousand patients with aplastic anemia have received an allogeneic HSCT after conditioning with CY alone, a non-myeloablative regimen, and these patients have now been followed for up to 30 years. Among surviving patients, 65% have full donor hematopoiesis, 20% are stable mixed chimeras and 15% are 'progressive' mixed chimeras and have returned to autologous hematopoiesis.
Mixed chimerism is associated with less chronic GVHD and decreased transplant toxicity. The intensity of the conditioning regimen is one of the factors which influences the degree of mixed chimerism: in thalassemia patients conditioned with 14 mg/kg busulfan (BU) and CY either 200 mg/kg, 160 mg/kg or 120 mg/kg the proportion of mixed chimeras at 2 months is respectively 20%, 60% and 70%. Therefore, reducing the dose of CY will increase the number of patients with mixed chimerism or chronic rejection. The level of chimerism required to correct any given hematologic or non-hematologic disease remains to be determined. It would seem that in the acute leukemias complete chimerism is essential. In other disorders it may not be.
Tolerance can also be induced in the absence of complete chimerism as shown by the Seattle group, where 2 Gy TBI followed by cyclosporin (CyA)/mycophenolate mofetil (MMF) can induce significant engraftment and tolerance in the canine model and also in humans. The clear message of this experience is that not only the intensity of the conditioning but also the intensity of in vivo immunosuppression is relevant to the engraftment dynamics and immune reactions.
Tolerance could also be affected by the use of other agents. IL-10 downregulates receptors for the CD28 ligand, ICAM-1 and MHC class II expression and induces alloantigen unresponsiveness and long-lasting anergy. The constitutive IL-10 production prior to BMT seems to be indeed higher in patients who do not develop GVHD.
Ongoing trials in humans
Different conditioning regimens were discussed at the workshop: fludarabine-based programs, the TBI 2 Gy schedule, thiotepa-based conditioning regimens and the autologous mini-allo program. Variations of these regimens with the inclusion of anthracyclines, melphalan, higher doses of cyclophosphamide, thymic irradiation, antithymocyte globulin, low-dose busulfan were also discussed. Results can be summarized as follows:
• There is a great variety of preparative regimens in terms of number and doses of utilized drugs • Most programs include in vivo immunosuppression and unmanipulated peripheral blood mobilized cells • Most patients achieve engraftment • Many achieve complete remission of their underlying disease • Patients with chronic disorders and lymphoma seem to do better than patients with leukemia, myelodysplasia or myeloma • Some patients with breast cancer may also benefit from the procedure • Toxicity is reduced, but deaths due to acute and chronic GVHD, as well as infections are seen • Significant immune deficiency was reported in almost all patients • Long-term results on the control of malignancy are not available because of the short follow-up
Is a graft-versus-leukemia effect required?
The existence of a GVL effect is now widely accepted. The contribution of this effect to the cure of malignancy is less well defined and may be quite variable in different systems.
In the mouse a spontaneous B cell lymphoma can be cured following cell therapy alone, that is to say without the need to reduce the tumor with chemotherapy or radiotherapy, provided the lymphocytes include CD8 + cells. In patients who relapse with acute leukemia after an allogeneic transplant donor lymphocyte infusions may be totally ineffective. It is possible that the GVL or graft-versus-tumor effect, must be combined in most instances with tumor cell reduction, and therefore with chemoradiotherapy. Indeed, the original bone marrow transplant program is a combination of cytoreduction followed by stem cell engraftment and immune intervention, all in one. As conditioning programs become less intense, the need for early infusion of donor lymphocytes increases: this may carry the risk of acute GVHD and studies are ongoing with different doses of lymphocytes, different lymphocyte subsets and genetically modified lymphocytes. There is no standard approach which can be recommended at present: the early use of lymphocytes infusions must be regarded with caution and probably numbers below 1 × 10 6 /kg should be considered.
Consensus
The consensus of this workshop can be summarized as follows:
• The term mini-transplant is probably misleading and reduced intensity allogeneic HSCT (RI-HSCT) is preferred • RI-HSCT is an experimental procedure • RI-HSCT involves the use of normal donors, and ethical issues apply as with any allogeneic transplant • Donors should be carefully evaluated because their (probable) older age exposes them to an increased risk of lethal complications • At present RI-HSCT should be offered to patients who are otherwise not eligible for conventional allogeneic HSCT • Acute leukemia and myelodysplastic patients are probably not good candidates • RI-HSCT may be appropriate in chronic disorders such as chronic lymphoproliferative diseases. Chronic myeloid leukemia should be studied • Multiple myeloma patients may pose particular problems • It remains to be determined whether RI-HSCT is beneficial to patients with solid tumors • Immune reconstitution should be investigated further
Conclusions
The field of stem cell transplantation is evolving rapidly from standard cyclophosphamide/TBI and bone marrow, to many diverse conditioning regimens followed by manipulated grafts. The important discovery is that hematopoietic stem cell engraftment can be facilitated in many different ways: with intensive chemo-radiotherapy, with antibodies, with low-dose radiation, with large number of stem cells, with modified accessory cells. Stem cell engraftment, however, is not sufficient to cure leukemia, as shown by patients who relapse with the original leukemia but keep on producing donor-derived red blood cells.
We need to reduce the volume of the tumor either with some form of chemoradiotherapy, or with immune intervention or both. Therefore, stem cell engraftment should be considered an essential but not self-sufficient platform to cure tumors. More work is required on the identification of cells capable of promoting engraftment, mediating GVHD and the graft-versus-leukemia effect.
